Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.155
Neutral
RSI(14)
50.133
Neutral
STOCH(KDJ)(9,3,3)
25.666
Neutral
ATR(14)
9.368
Low Volatility
CCI(14)
-71.638
Neutral
Williams %R
72.639
Sell
TRIX(12,20)
0.233
Sell
StochRSI(14)
54.236
Buy
Grail Inc
GRAL100.070USD
+6.010+6.39%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.62BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Grail Inc
Currency: USD Updated: 2026-02-06Key Insights
Grail Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 86 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 105.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Grail Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Grail Inc Highlights
StrengthsRisks
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 126.09% year-on-year.
Undervalued
The company’s latest PE is -9.39, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.81M shares, decreasing 20.00% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.72K shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
105.000
Target Price
+11.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Grail Inc is 7.52, ranking 103 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 36.19M, representing a year-over-year increase of 26.32%, while its net profit experienced a year-over-year increase of 29.21%.
Score
Financials
6.20
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.37
Operational Efficiency
10.00
Growth Potential
6.85
Shareholder Returns
7.19
Grail Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Grail Inc is 7.47, ranking 117 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.39, which is -98.63% below the recent high of -0.13 and -15.98% above the recent low of -10.89.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 86/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Grail Inc is 7.50, ranking 284 out of 392 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 110.00 and a low of 100.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
105.000
Target Price
+11.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Grail Inc
GRAL
4
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Grail Inc is 7.18, ranking 95 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 114.94 and the support level at 89.10, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
100.420
Sell
MA10
101.719
Sell
MA20
102.371
Sell
MA50
98.355
Buy
MA100
85.794
Buy
MA200
61.910
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Grail Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 66.22%, representing a quarter-over-quarter decrease of 4.10%. The largest institutional shareholder is PRIMECAP Management, holding a total of 2.02M shares, representing 5.18% of shares outstanding, with 9.10% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Illumina Inc
BlackRock Institutional Trust Company, N.A.
CRCM L.P.
Baker Bros. Advisors LP
Farallon Capital Management, L.L.C.
State Street Investment Management (US)
Arbiter Partners Capital Management, LLC
Sessa Capital
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Grail Inc is 3.64, ranking 130 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+52.78%
240-Day Volatility
+100.85%
Return
Best Daily Return
60 days
+19.08%
120 days
+19.08%
5 years
--
Worst Daily Return
60 days
-10.98%
120 days
-10.98%
5 years
--
Sharpe Ratio
60 days
+1.19
120 days
+2.75
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+52.78%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+2.29
3 years
--
5 years
--
Skewness
240 days
+0.40
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+100.85%
5 years
--
Standardised True Range
240 days
+5.00%
5 years
--
Downside Risk-Adjusted Return
120 days
+592.20%
240 days
+592.20%
Maximum Daily Upside Volatility
60 days
+71.04%
Maximum Daily Downside Volatility
60 days
+49.16%
Liquidity
Average Turnover Rate
60 days
+3.17%
120 days
+3.55%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Grail Inc
GRAL
6.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
